Laboratorios Farmaceuticos Rovi revenue and financials

ROVI · BME · EUR

Compare Laboratorios Farmaceuticos Rovi
€63.10Change from previous close: −4.54%Absolute change: −€3.00

Close · November 20, 2026

In the fiscal year ended December 2025, Laboratorios Farmaceuticos Rovi reported revenue of €743.48M (−2.65% year over year). Net income was €140.44M, a net margin of 18.9%.

Annual revenue · 2025: €743.48M
  1. €265.17M2016
  2. €275.65M2017
  3. €303.2M2018
  4. €381.31M2019
  5. €419.96M2020
  6. €648.68M2021
  7. €817.7M2022
  8. €829.51M2023
  9. €763.75M2024
  10. €743.48M2025

Fiscal year ending in December. Sources and method on the page How we analyse stocks.

At a glance

Revenue growth
−2.65%
2025 vs 2024
Net income growth
+2.60%
2025 vs 2024
Net margin
18.9%
2024: 17.9%

How Laboratorios Farmaceuticos Rovi is changing

Calculated from the annual statements; each fiscal year is labelled with the year it ends.

Financial data

Amounts in millions of EUR; per-share values in EUR; shares in millions.

Income statement · Annual
Item2025202420232022202120202019201820172016
Total revenue743764830818649420381303276265
Cost of revenue272296346305269183170132114115
Gross profit472468483512380237211171162150
Selling, general and administrative16015814713010384.892.291.184.680.1
Operating income17317921925418074.942.015.915.222.7
EBIT17317921925418074.942.015.915.222.7
EBITDA19620023827119789.655.427.025.432.6
Interest expense2.62.00.90.80.91.10.60.71.00.9
Pre-tax income18317822025818372.641.916.717.527.9
Income tax42.940.850.158.329.611.52.6-1.20.31.8
Net income14013717020015361.139.317.917.226.1
Net income to common shareholders14013717020015361.139.317.917.226.1
Basic EPS2.752.673.203.732.761.100.710.350.350.53
Diluted EPS2.752.673.203.732.761.100.710.350.350.53
Average shares (basic)51.151.253.253.555.455.455.251.249.349.3
Average shares (diluted)51.151.253.253.555.455.455.251.249.349.3
Dividend per share0.960.941.101.290.960.380.180.080.120.18

Companies in the group: same industry, similar size